Form 4: Avadel Pharmaceuticals Director Transfers Stock Options to Revocable Trust

Director Geoffrey Michael Glass transferred 11,000 stock options to a revocable trust on September 13, 2024.

Summary

• On September 13, 2024, Geoffrey Michael Glass, a director of Avadel Pharmaceuticals PLC, filed a Form 4 to report changes in beneficial ownership.
• Glass transferred 11,000 stock options to the Geoffrey M. Glass Revocable Trust, of which he is the trustee and sole beneficiary along with his immediate family.
• The options have an exercise price of $16.32 and were granted on July 30, 2024.
• The options will vest on the earlier of July 30, 2025, or the date of the next annual general meeting following the grant date, contingent upon Glass's continued service.
• The expiration date for the options is July 30, 2034.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing detailing a routine transfer of stock options. It doesn't inherently convey positive or negative sentiment.

Industry Context

This filing is a routine disclosure related to insider transactions and is common for publicly traded companies. It provides transparency into the holdings and transactions of company insiders.

Related Party Transactions

• The transfer of stock options to the Geoffrey M. Glass Revocable Trust, of which the reporting person is trustee and beneficiary, constitutes a related party transaction.

Stakeholder Impact

• The transaction itself has minimal direct impact on stakeholders.
• It provides transparency to shareholders regarding insider transactions.

Key Dates